JP2005506295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005506295A5 JP2005506295A5 JP2002576275A JP2002576275A JP2005506295A5 JP 2005506295 A5 JP2005506295 A5 JP 2005506295A5 JP 2002576275 A JP2002576275 A JP 2002576275A JP 2002576275 A JP2002576275 A JP 2002576275A JP 2005506295 A5 JP2005506295 A5 JP 2005506295A5
- Authority
- JP
- Japan
- Prior art keywords
- formulas
- treatment
- compounds
- compound
- viii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 130
- 238000000034 method Methods 0.000 claims 75
- 238000011282 treatment Methods 0.000 claims 72
- 230000008568 cell cell communication Effects 0.000 claims 22
- 238000002360 preparation method Methods 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 14
- 206010003119 arrhythmia Diseases 0.000 claims 11
- 230000006793 arrhythmia Effects 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 230000002265 prevention Effects 0.000 claims 10
- 208000027418 Wounds and injury Diseases 0.000 claims 8
- 230000001771 impaired effect Effects 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 230000006378 damage Effects 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- -1 various isomers Chemical compound 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 206010052428 Wound Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000003976 gap junction Anatomy 0.000 claims 5
- 230000035876 healing Effects 0.000 claims 5
- 102000010970 Connexin Human genes 0.000 claims 4
- 108050001175 Connexin Proteins 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- MTAWKURMWOXCEO-UHFFFAOYSA-N taspine Chemical compound O1C(=O)C2=C(CCN(C)C)C=C(OC)C3=C2C2=C1C(OC)=CC=C2C(=O)O3 MTAWKURMWOXCEO-UHFFFAOYSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 208000016354 hearing loss disease Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000035992 intercellular communication Effects 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 238000010172 mouse model Methods 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010065687 Bone loss Diseases 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 2
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 208000007984 Female Infertility Diseases 0.000 claims 2
- 206010017076 Fracture Diseases 0.000 claims 2
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 2
- 208000004547 Hallucinations Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021928 Infertility female Diseases 0.000 claims 2
- 208000035901 Ischaemic ulcer Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 2
- 208000007466 Male Infertility Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033557 Palpitations Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 206010042600 Supraventricular arrhythmias Diseases 0.000 claims 2
- 208000001871 Tachycardia Diseases 0.000 claims 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 2
- 229930013930 alkaloid Natural products 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000002785 anti-thrombosis Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000001746 atrial effect Effects 0.000 claims 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 2
- KWEDUNSJJZVRKR-UHFFFAOYSA-N carbononitridic azide Chemical group [N-]=[N+]=NC#N KWEDUNSJJZVRKR-UHFFFAOYSA-N 0.000 claims 2
- 206010061592 cardiac fibrillation Diseases 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 230000006020 chronic inflammation Effects 0.000 claims 2
- 201000000159 corneal neovascularization Diseases 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002600 fibrillogenic effect Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229940016667 resveratrol Drugs 0.000 claims 2
- 235000021283 resveratrol Nutrition 0.000 claims 2
- 230000009759 skin aging Effects 0.000 claims 2
- 230000006794 tachycardia Effects 0.000 claims 2
- RKEBJJCZAOFMLH-UHFFFAOYSA-N taspine Natural products COc1ccc2OC(=O)c3c(OC)cc(CN(C)C)c4OC(=O)c1c2c34 RKEBJJCZAOFMLH-UHFFFAOYSA-N 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- YQAXFVHNHSPUPO-RNJOBUHISA-N 2-[[(2s)-2-[[2-[[(2s,4r)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@H]1N(C(=O)CN)CCC1 YQAXFVHNHSPUPO-RNJOBUHISA-N 0.000 claims 1
- SIMYWHHAEQQGEH-MAZDBSFSSA-N 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1.C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 SIMYWHHAEQQGEH-MAZDBSFSSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 235000021357 Behenic acid Nutrition 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- 208000035484 Cellulite Diseases 0.000 claims 1
- 208000026845 Cochlear disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000028006 Corneal injury Diseases 0.000 claims 1
- DCXYFEDJOCDNAF-UWTATZPHSA-N D-Asparagine Chemical compound OC(=O)[C@H](N)CC(N)=O DCXYFEDJOCDNAF-UWTATZPHSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 206010061309 Neoplasm progression Diseases 0.000 claims 1
- 241000208125 Nicotiana Species 0.000 claims 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims 1
- 101800000989 Oxytocin Proteins 0.000 claims 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010049752 Peau d'orange Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000028990 Skin injury Diseases 0.000 claims 1
- 206010072170 Skin wound Diseases 0.000 claims 1
- 208000026062 Tissue disease Diseases 0.000 claims 1
- 206010060872 Transplant failure Diseases 0.000 claims 1
- 208000000921 Urge Urinary Incontinence Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 210000004198 anterior pituitary gland Anatomy 0.000 claims 1
- 108010082685 antiarrhythmic peptide Proteins 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 229940116226 behenic acid Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000001715 carotid artery Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000036232 cellulite Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 238000004891 communication Methods 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 208000021921 corneal disease Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 231100000895 deafness Toxicity 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 210000003981 ectoderm Anatomy 0.000 claims 1
- 210000001900 endoderm Anatomy 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 230000007387 gliosis Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 235000001705 insufficient nutrition Nutrition 0.000 claims 1
- 229950010984 irsogladine Drugs 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 210000003716 mesoderm Anatomy 0.000 claims 1
- 230000006609 metabolic stress Effects 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 235000003715 nutritional status Nutrition 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 1
- 229960001723 oxytocin Drugs 0.000 claims 1
- 102000014187 peptide receptors Human genes 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000002000 scavenging effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 230000005751 tumor progression Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000006496 vascular abnormality Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
- 0 *C(*)NC(*)C(*)*N* Chemical compound *C(*)NC(*)C(*)*N* 0.000 description 2
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/792,286 US7250397B2 (en) | 2000-02-23 | 2001-02-22 | Antiarrhythmic peptides |
| PCT/DK2001/000127 WO2001062775A2 (en) | 2000-02-23 | 2001-02-22 | Novel antiarrhythmic peptides |
| US31447001P | 2001-08-23 | 2001-08-23 | |
| PCT/US2002/005773 WO2002077017A2 (en) | 2001-02-22 | 2002-02-22 | Medical uses of intercellular communication facilitating compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005506295A JP2005506295A (ja) | 2005-03-03 |
| JP2005506295A5 true JP2005506295A5 (sr) | 2006-01-05 |
Family
ID=27222186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002576275A Pending JP2005506295A (ja) | 2001-02-22 | 2002-02-22 | 細胞間連絡促進化合物の新規医薬使用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1370276B1 (sr) |
| JP (1) | JP2005506295A (sr) |
| AT (1) | ATE497967T1 (sr) |
| IL (1) | IL157447A0 (sr) |
| MX (1) | MXPA03007537A (sr) |
| WO (1) | WO2002077017A2 (sr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250397B2 (en) | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| CN1638790A (zh) | 2002-01-29 | 2005-07-13 | Wyeth公司 | 用于调节连接蛋白半通道的组合物和方法 |
| NZ540155A (en) * | 2002-11-25 | 2006-11-30 | Zealand Pharma As | Peptides that modulate gap junction intercellular communication (GJIC).for use in the treatment or prevention of pathologies associated with impaired GJIC |
| EP1723163A2 (en) * | 2003-12-23 | 2006-11-22 | Wyeth a Corporation of the State of Delaware | Isopeptide gap junction modulators |
| DE102005005270A1 (de) * | 2005-02-04 | 2006-08-10 | Peter Heger | Verwendung von Hydroxystilben-haltigen Wirkstoffen zur Behandlung leichter bis mittelschwerer Depressionen und Angstzustände |
| GB0514071D0 (en) | 2005-07-07 | 2005-08-17 | Zealand Pharma As | N- or C- terminally modified small peptides |
| UA96283C2 (uk) | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| PL2468724T3 (pl) | 2006-12-21 | 2016-05-31 | Zealand Pharma As | Synteza związków pirolidynowych |
| US20100298225A1 (en) * | 2007-07-15 | 2010-11-25 | Bjarne Due Larsen | Peptide gap junction modulators |
| WO2010026487A1 (en) * | 2008-09-08 | 2010-03-11 | University Of Concepcion | Therapeutic methods and compositions |
| GB201512139D0 (en) * | 2015-07-10 | 2015-08-19 | Zealand Pharma As | Methods of treatment |
| JP6989864B2 (ja) | 2017-05-05 | 2022-02-03 | ジーランド ファーマ，アー／エス | ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用 |
| WO2021159011A1 (en) | 2020-02-07 | 2021-08-12 | United States Government As Represented By The Department Of Veterans Affairs | Method for treating nervous system injuries using boldine and analogs thereof |
| CN118450892A (zh) | 2021-12-22 | 2024-08-06 | 布雷耶疗法有限公司 | 缝隙连接调节剂及其用于治疗年龄相关性黄斑变性的用途 |
| GB202310195D0 (en) * | 2023-07-03 | 2023-08-16 | Hastings Nataly | Method for mitigating symptoms of neurological condition and a system therefor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19500990A1 (de) * | 1995-01-14 | 1996-07-18 | Stefan Dr Med Dhein | Neues Peptid, seine Herstellung und Verwendung |
| DE19707854A1 (de) * | 1997-02-27 | 1998-09-03 | Dhein Stefan Priv Doz Dr Med | Neue Cyclopeptide, deren Herstellung und Verwendung |
| WO2001062775A2 (en) * | 2000-02-23 | 2001-08-30 | Zealand Pharma A/S | Novel antiarrhythmic peptides |
-
2002
- 2002-02-22 IL IL15744702A patent/IL157447A0/xx unknown
- 2002-02-22 JP JP2002576275A patent/JP2005506295A/ja active Pending
- 2002-02-22 WO PCT/US2002/005773 patent/WO2002077017A2/en not_active Ceased
- 2002-02-22 AT AT02723240T patent/ATE497967T1/de not_active IP Right Cessation
- 2002-02-22 EP EP02723240A patent/EP1370276B1/en not_active Expired - Lifetime
- 2002-02-22 MX MXPA03007537A patent/MXPA03007537A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12351651B2 (en) | Polypeptide for repairing mucosal damage or skin wound and use thereof | |
| JP2005506295A5 (sr) | ||
| JP4173914B2 (ja) | Ｏｂ蛋白組成物を用いる非脂肪組織重増加方法 | |
| US8183343B2 (en) | Methods for treating a skin wound | |
| US20020147142A1 (en) | Methods and reducing or maintaining reduced levels of blood lipids using OB protein compositions | |
| US20070207180A1 (en) | Synthetic polypeptide-containing bioapplicable material and film-forming material | |
| JPH01121300A (ja) | 乳汁に由来するポリペプチド成長因子 | |
| CA2997131C (en) | Long-acting adrenomedullin derivative | |
| CN115867321B (zh) | 具有抗肥胖活性的脱氧胆酸-肽缀合物及其用途 | |
| CN102883736A (zh) | 用于促进血管生成的肽及其用途 | |
| JP2002542298A (ja) | 低分子量トロンビン阻害物質およびそのプロドラッグを含む医薬製剤 | |
| CN114106100B (zh) | 用于修复皮肤创伤或黏膜损伤的多肽及其应用 | |
| JPH0242026A (ja) | 関節炎の処置 | |
| US7208577B2 (en) | Methods of increasing lean tissue mass using OB protein compositions | |
| JPH05503103A (ja) | 障害を受けた組織における血管漏洩を抑制する抗炎症ペプチド及びその組織の治療方法 | |
| US5616558A (en) | Medicaments comprising glicentin as active ingredient | |
| JPH06510754A (ja) | 食欲不振および関連症状の治療用のアミリンおよび可能性としてインスリンを含有する組成物 | |
| CA2439101A1 (en) | New medical uses of intercellular communication facilitating compounds | |
| US20130296226A1 (en) | Methods and compositions for the treatment of metabolic disorders | |
| CN114805489A (zh) | 一类用于修复皮肤损伤或黏膜损伤的多肽及其应用 | |
| WO2010085661A1 (en) | Modified peptides and their use | |
| CN116003529A (zh) | 多肽及其在修复黏膜损伤或皮肤损伤上的应用 | |
| HK40090321A (en) | Polypeptide for repairing mucosal damage or skin wound and use thereof | |
| HK40118093A (en) | Treatment method using mazdutide | |
| JPH0272123A (ja) | ヒト上皮細胞成長因子の投与方法及びヒト上皮細胞成長因子含有疾病治療剤 |